PolyModels Hub

Polymodels is a life sciences software company that has developed ModelFlow, a unified digital platform purpose-built for pharmaceutical process development. Described as the "digital backbone for pharma process development" and created by scientists and engineers with deep biopharma backgrounds, Polymodels connects data, models, and teams into a single integrated environment designed to accelerate drug development, improve collaboration, and deliver measurable return on investment.

The platform serves biopharmaceutical organizations across R&D, process development, and manufacturing, supporting the full product lifecycle from early lab-scale experimentation through large-scale commercial production. Polymodels combines mechanistic modeling, digital twins, AI, and workflow automation to transform fragmented development steps into an optimized, reproducible process.

ModelFlow Platform Capabilities

• Provides a unified platform connecting data, models, and cross-functional teams for faster and more reliable biopharma progress
• Offers tailored model recommendations that support robust process and product development across the full development lifecycle
• Enables in-silico simulation to design experiments efficiently, collect results, and reach insights faster — reducing the need for costly physical experiments
• Supports end-to-end digital twin development for complex unit operations including reactive crystallization, filtration, washing, drying, and continuous manufacturing processes
• Facilitates virtual Design of Experiments (DoE) and risk analysis to minimize large-scale batch runs and confirmatory experiments
• Enables scale-up to be achieved digitally, eliminating the need for multiple experiments at scale
• Derives actionable insights from process, lab, and operations data to enhance yield and reduce suboptimal production
• Supports standardized models across multiple manufacturing sites to achieve reproducible results
• Allows teams to manage every aspect of projects, showcase clear ROIs, and collaborate across departments

Therapeutic Modality Coverage

• Small Molecule: Core treatments with precise targeting and established efficacy
• Oligonucleotides: Next-generation therapies using synthetic DNA or RNA fragments
• Biopharm & Sterile: Advanced biological therapies and sterile formulations for critical care
• Vaccines: Protective immunizations leveraging cutting-edge biotechnological advances
• The platform includes libraries of workflows structured to handle any of these therapeutic modalities effectively

Demonstrated Customer Outcomes

• For a Global Biopharmaceutical Leader, ModelFlow's end-to-end digital twin for reactive crystallization, filtration, washing, and drying replaced 80+ lab experiments through in-silico simulation, informed a $200M facility investment decision, saved 3+ months of development time, and achieved scale-up from 2L to 10,000L digitally — eliminating 12 experiments at scale
• For a Top 5 Global Healthcare Company, the platform identified 50+ suboptimal batches representing approximately 10% of yearly production, captured an estimated $60M per year in annual value after implementing process changes, standardized models across 4+ manufacturing sites, and recovered 150+ process days by avoiding rework
• For a Leading European Pharmaceutical Company, ModelFlow's end-to-end modeling for a new continuous manufacturing process reduced 100+ lab experiments using in-silico runs, saved $3M in development costs, saved 3+ months in development time, and avoided 10+ large-scale batch runs
• For another Top 5 Global Healthcare Company, digital workflows optimized Protein A resin usage and accelerated scale-up for a second-generation biologic, delivering a 4-cycle optimized plan, $2M per year in savings through in-silico resin cycle optimization, 4 large-scale campaign time savings via virtual DoE and risk analysis, and process validation requiring only 2 confirmatory experiments

Team and Expertise

• Polymodels was founded by a team with deep biopharma R&D and manufacturing expertise combined with AI and software engineering capabilities
• The founding team includes a Chief Executive Officer, a Chief Scientific Officer (PhD), and a Chief Technology Officer
• The core team comprises R&D scientists who develop and deploy digital twins and mechanistic models to solve complex R&D challenges
• Software engineers build the scalable, secure, and AI-powered infrastructure underpinning ModelFlow, connecting modeling interfaces and workflows
• Workflow architects connect models, data, and teams into seamless digital workflows that enable collaboration and accelerate decision-making across the biopharma value chain
• The broader team includes senior MLOps and process modeling engineers, data scientists, bioprocess modeling engineers, and industrial data science specialists

Polymodels is built on the mission to accelerate pharmaceutical process development and ultimately transform lives, offering a science-driven, practical, and robust digital solution ready for real-world deployment across labs, development functions, and manufacturing operations.